Virtual Library
Start Your Search
P. Ganesan
Author of
-
+
P3.07 - Poster Session/ Small Cell Lung Cancer (ID 223)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.07-018 - Outcomes in Small Cell Lung Cancer in India: A 15 Year Retrospective Analysis (ID 1052)
09:30 - 09:30 | Author(s): P. Ganesan
- Abstract
Background:
Small Cell Lung Cancer has a aggressive clinical course and poor outcomes. Role of multi modality therapy and prophylactic cranial irradiation have been established in the last two decades. There is a paucity of studies on survival in SCLC in India and to our knowledge till date; only one study has been published from India. The current study is a retrospective review of outcomes in patients with SCLC in India
Methods:
All newly diagnosed small cell lung cancer cases from 2000 through 2014 who received treatment at Cancer Institute (WIA),Chennai were identified and clinical data from their hospital records, noted. The influence of various pretreatment factors on survival was investigated using Kaplan-Meier plots and Cox multivariate regression model. Only subjects who received intravenous chemotherapy were included in the analysis.
Results:
Forty seven subjects were included, 39 (83%) were males. Age distribution: Less than 50 years – 16 (34%), 50-59 years - 16 (34%),> 60 years – 15 (32%). Limited Stage: 21 (44.6%) and extensive stage: 26 (55.4%). Treatment outcomes in Limited stage disease (N=21): Sequential chemotherapy and radiation: N=11 (52.38%), median PFS was 8 months, 1 year OS was 72.9% (P<0.001) and 5 year OS was 0%. Concurrent chemotherapy and radiation: N=10 (47.62%), median PFS was 10 months, 1 year OS was 78.8% and 5 year OS was 26.3% (P<0.001). The improvement in overall survival when subjects received concurrent chemotherapy and radiation as compared to sequential chemotherapy and radiation was statistically significant (P<0.001). Treatment outcomes in Extensive stage disease (N=26); Chemotherapy alone: N=19 (73%),1 year PFS was 6.8% and 1 year OS was 9.1%, Sequential chemotherapy and radiation: N=7 (17%), 1 year PFS was 28.6% and 1 year OS was 53.6% (P=0.075). There were no survivors at 5 years in subjects with extensive stage disease irrespective of whether chemotherapy alone was used or sequential chemotherapy and radiation. In subjects with limited stage disease 9, (42.85%) received prophylactic cranial irradiation
Conclusion:
Subjects with limited stage disease who received concurrent chemo-radiation showed a better overall survival as compared to those who received sequential chemo-radiation. Subjects with extensive stage disease who underwent sequential chemo-radiation did not show any statistically significant improvement in overall survival as compared to those who received only chemotherapy. Concurrent chemo-radiation should be the preferred treatment approach in limited stage SCLC in spite of the significant increase in costs and side effect profile even in developing countries. Sequential chemo-radiation may not show any added advantage in extensive stage SCLC especially considering the added side effects as well as the burden on resources
